… patients without IPF who develop COVID-19 pneumonia, acute lung injury, and ARDS.
Finally, we consider the fibrotic consequences for patients who survive COVID-19-related ARDS. …

… proportion of post covid lung fibrosis is worrisome. … covid pulmonary fibrosis. This narrative
review summarizes current clinical evidence regarding post COVID-19 pulmonary fibrosis. …

… reduce the risk of pulmonary fibrosis in severe cases of COVID-19; however, … COVID-19
with ARDS [18]. This review provides an overview of pulmonary fibrosis resulting from COVID-19 …

… -COVID-19 pulmonary fibrosis and the potential risk factors. … ; Pulmonary fibrosis is a
frequently reported COVID-19 … prevalence of post-COVID-19 pulmonary fibrosis (PCPF) and …

… Of note, the average age of patients hospitalised with severe COVID-19 appears to be … of
pulmonary fibrosis. Given these observations, the burden of pulmonary fibrosis after COVID-19 …

… could also be under consideration based on the pulmonary fibrotic disease observed
after COVID-19 recovery (33). Pirfenidone exerts anti-fibrotic, anti-oxidative and anti-inflammatory …

… treatment for post-COVID pulmonary fibrosis are not completely determined yet. Therefore,
this review describes the current evidence of post-COVID-19 pulmonary fibrosis, including the …

… in COVID-19 infection. We evaluate the evidence in support of the putative risk factors for the
development of lung fibrosis … , the predictors of pulmonary fibrosis in COVID-19 infection are …

… on the development of interstitial pulmonary fibrosis is not specific to COVID-19 but well-… a
link between hypoxia and the development of pulmonary fibrosis, citing the aberrant interplay …

… whether patients after COVID-19 who present with signs of pulmonary fibrosis should receive
specific antifibrotic drugs, due to the fact that pulmonary fibrosis after COVID-19 is typically …